Crohn's Disease News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Perianal Crohn's Disease with Abscesses, Fissures, and Fistulas - IBD News Today



IBD News Today
 
Perianal Crohn's Disease with Abscesses, Fissures, and Fistulas 
IBD News Today
Columnist Mary Horsley discusses perianal Crohn's disease's symptoms and her experience with treating it through surgical means.

and more » 


FDA OKs Clinical Trial to Test Bacteriophage-Based Treatment for Crohn's - IBD News Today



IBD News Today
 
FDA OKs Clinical Trial to Test Bacteriophage-Based Treatment for Crohn's 
IBD News Today
The U.S. Food and Drug Administration (FDA) recently cleared a Phase 1/2a clinical trial to study a set of bacteriophages designed to treat inflammatory bowel diseases (IBDs), specifically Crohn's disease. The bacteriophages were developed as part of a ...

 


US to see increase in Crohn's disease: 4 things to know - Becker's ASC Review



US to see increase in Crohn's disease: 4 things to know 
Becker's ASC Review
With the exception of Germany, all countries in the seven major markets ? the U.S., France, Germany, Italy, Spain, U.K. and Japan ? will see an increase in diagnosed cases of Crohn's disease. 2. The largest increases are expected in the U.S., France ...

 


AbbVie Presents New Data on Upadacitinib for Crohn's Disease - Zacks.com



Zacks.com
 
AbbVie Presents New Data on Upadacitinib for Crohn's Disease 
Zacks.com
The 52-week CELEST study evaluated upadacitinib in multiple dosing regimens through week 52 in adult patients with Crohn's disease and who were intolerant or had inadequate response to an immunomodulator or tumor necrosis factor alpha antagonist (TNF-a ...
Oral JAK1 inhibitor upadacitinib maintains response in Crohn's through 1 year Healio

all 3 news articles » 


Global Crohn's Disease Forecast to 2025 - ResearchAndMarkets.com - Business Wire (press release)



Global Crohn's Disease Forecast to 2025 - ResearchAndMarkets.com 
Business Wire (press release)
The growth in the Crohn's disease market comes despite downward pressure from the entry of biosimilars of the key marketed anti-tumor necrosis factor biologics, Remicade and Humira, which will be marketed at a lower cost than the reference brands ...
Global Crohn's Disease Forecast to 2025 - ResearchAndMarkets ... Digital Journal

all 1 news articles » 


5 Things to Know About Biosimilars and Inflammatory Bowel Disease - AJMC.com Managed Markets Network



5 Things to Know About Biosimilars and Inflammatory Bowel Disease 
AJMC.com Managed Markets Network
5 Things to Know About Biosimilars and Inflammatory Bowel Disease. Kelly Davio. Last week, the European Crohn's and Colitis Organisation held its 13th annual congress in Vienna, Austria. At the meeting, researchers presented new data on using ...

 


"Intestine-Chip" Could Help Patients With Diseases Like Crohn's - Futurism



Futurism
 
"Intestine-Chip" Could Help Patients With Diseases Like Crohn's 
Futurism
Using an Intestine-Chip, researchers could improve care for people with debilitating gastrointestinal conditions and research into organ function.

and more » 


Crohn's Progression Unchanged Despite Advanced Therapies - Medscape



Medscape
 
Crohn's Progression Unchanged Despite Advanced Therapies 
Medscape
Use of advanced therapies for Crohn's disease (CD) has not significantly altered the natural disease course and phenotypes compared with those reported before the era of biologic therapies, a recent study suggests. "Despite an earlier and more ...

 


Crohn's Disease Market Size and Top Key Players in 2022; By ... - Medgadget (blog)



Crohn's Disease Market Size and Top Key Players in 2022; By ... 
Medgadget (blog)
Crohn's disease is a kind of inflammatory bowel sickness (IBD), caused by a mixture of environmental, immune and bacterial elements in genetically prone in.

and more » 


Crohn's Disease Study Indicates Positive Results For Celltrion's Biosimilar Infliximab - Pharmaceutical Processing



Crohn's Disease Study Indicates Positive Results For Celltrion's Biosimilar Infliximab 
Pharmaceutical Processing
CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world study. Twelve-month data from the Personalized Anti-TNF therapy in Crohn's disease Study (PANTS) was presented at the 13th Congress of ...